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Abstract
Purpose: Prostate cancer (PCa) is characterized by deregulated expression of several tumor suppressor or oncogenic
miRNAs. The objective of this study was the identification and characterization of miR-let-7c as a potential tumor suppressor
in PCa.
Experimental Design: Levels of expression of miR-let-7c were examined in human PCa cell lines and tissues using qRT-PCR
and in situ hybridization. Let-7c was overexpressed or suppressed to assess the effects on the growth of human PCa cell
lines. Lentiviral-mediated re-expression of let-7c was utilized to assess the effects on human PCa xenografts.
Results: We identified miR-let-7c as a potential tumor suppressor in PCa. Expression of let-7c is downregulated in castration-
resistant prostate cancer (CRPC) cells. Overexpression of let-7c decreased while downregulation of let-7c increased cell
proliferation, clonogenicity and anchorage-independent growth of PCa cells in vitro. Suppression of let-7c expression
enhanced the ability of androgen-sensitive PCa cells to grow in androgen-deprived conditions in vitro. Reconstitution of Let-
7c by lentiviral-mediated intratumoral delivery significantly reduced tumor burden in xenografts of human PCa cells.
Furthermore, let-7c expression is downregulated in clinical PCa specimens compared to their matched benign tissues, while
the expression of Lin28, a master regulator of let-7 miRNA processing, is upregulated in clinical PCa specimens.
Conclusions: These results demonstrate that microRNA let-7c is downregulated in PCa and functions as a tumor suppressor,
and is a potential therapeutic target for PCa.
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Introduction
Prostate cancer (PCa) is the most commonly occurring
malignancy and the second most frequent cause of cancer-related
mortality in men in the US. The majority of patients with
advanced PCa respond initially to androgen deprivation therapy,
but relapse due to the growth of castration resistant prostate
cancer (CRPC) cells. Significant efforts have been focused on
understanding the mechanisms involved in the development and
progression of CRPC. MicroRNAs (miRNAs) are endogenous
small non-coding RNAs that can interfere with protein expression
either by inducing cleavage of their specific target mRNAs or by
inhibiting their translation. Mature miRNAs are evolutionarily
conserved ,22nt single stranded RNAs resulting from a multistep
processing of larger precursor molecules via Drosha and Dicer.
Eventually the mature miRNAs are incorporated into the RISC
complex along with their target mRNAs which are recognized by
sequence complementarity in the 3’-UTR [1]. Each miRNA can
target several different mRNAs and each mRNA can be targeted
by multiple miRNAs, generating an intricate network of gene
expression regulation. MiRNAs have been shown to regulate a
rapidly increasing list of complex biological processes including
differentiation, cell cycle, apoptosis and metabolism [2]. An
overwhelming amount of new evidence points to their roles as
tumor suppressors or oncogenes which presents a whole spectrum
of novel diagnostic and therapeutic opportunities [1,3].
Let-7 encodes an evolutionarily conserved family of 13
homologous miRNAs located in genomic locations frequently
deleted in human cancers [4]. Expression of let-7 in lung cancer
cell lines reduced cell proliferation [5] and inhibited tumorigenesis
of breast cancer cells while also reducing metastases [6].
Overexpression of let-7 also decreased lung cancer cell resistance
to radiation therapy [7]. Reduced expression of let-7 in human
lung cancers has been associated with shortened post-operative
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marker in lung cancer [8]. Similarly, 5-year progression free
survival rate was found to be higher in ovarian cancer patients
with lower HMGA2/let-7 ratios compared to those with higher
HMGA2/let-7 ratios [9]. There is an evident link between loss of
let-7 expression and development of poorly differentiated and
aggressive cancers [10]. Let-7 expression was found to be
downregulated in localized PCa tissues relative to benign
peripheral zone tissue [11,12]. Let-7 members have been shown
to regulate expression levels of oncogenes like HMGA2 [5], RAS
[13] and Myc [14] along with genes involved in cell cycle and cell
division regulation. Therapeutic strategies are being developed
targeting let-7, using either lenti-or adeno-viral-encoded overex-
pression of let-7 or transient transfection of double-stranded
precursors of let-7 [15,16]. Thus, let-7 shows promise as a
molecular marker in certain cancers and as a potential therapeutic
in cancer treatment.
Lin28, a highly conserved RNA-binding protein and a master
regulator of let-7 miRNA processing, is overexpressed in primary
human tumors [17,18] and is postulated to be one of the
embryonic stem cell factors that promote oncogenesis and
proliferation of cancer cells, by repression of the let-7 family of
tumor suppressors [19]. Lin28 binds to the terminal loops of the
precursors of let-7 family miRNAs and blocks their processing into
mature miRNAs [20,21]. Lin28 also derepresses c-Myc by
repressing let-7 and c-Myc transcriptionally activates Lin28
[22,23]. This Lin28/let-7/c-Myc loop may play an important
role in the deregulated miRNA expression signature observed in
many cancers [24].
In this study, we demonstrate that let-7c, one of the members of
the let-7 family, suppresses PCa growth in vitro and in vivo.
Overexpression of let-7c led to inhibition of anchorage-dependent
as well as anchorage-independent growth of PCa cells. Reexpres-
sion of let-7c in xenografts of human PCa cells using lentivirally
encoded let-7c inhibited tumor growth significantly. In addition,
let-7c expression is downregulated in clinical PCa specimens. Our
results imply that prostate tumor growth is regulated by let-7c and
that reconstitution of let-7 may have beneficial effects in PCa by
decreasing survival and proliferation of tumor cells.
Materials and Methods
Cell lines and Reagents
LNCaP, C4-2B, PC-346C and DU145 cells were obtained from
the American Type Culture Collection (ATCC, Manassas, VA).
LNCaP, C4-2B and PC346C cells are androgen receptor (AR)
positive and respond to androgen supplementation, while DU145
cells are AR negative and are androgen-insensitive. LNCaP-S17
and LNCaP-IL6+ cell lines were generated in our laboratory by
stable transfection of full length IL-6 cDNA into LNCaP cells and
by chronic treatment of LNCaP cells with 5 ng/ml recombinant
IL-6 respectively. Both cell lines exhibit autocrine IL-6 signaling.
Antibodies against Actin and Tubulin were purchased from Santa
Cruz Biotechnologies (Santa Cruz, CA). Lin28 antibodies were
obtained from Abcam (San Francisco, CA). SYBR Green iQ
Supermix was from Bio-Rad. Lentivector-based let-7c construct
was obtained from System Biosciences and Lin28 ORF and
shRNA constructs were obtained from Open Biosystems.
Western Blot Analysis
Cells were lysed in high salt buffer containing 50 mM Hepes pH
7.9, 250 mM NaCl, 1 mM EDTA, 1% NP-40, 1 mM PMSF,
1 mM Na Vanadate, 1 mM NaF and protease inhibitor cocktail
(Roche) as described earlier [25]. Total protein was estimated
using the Coomassie Protein Assay Reagent (Pierce, Rockford, IL).
Equal amounts of protein were loaded on 10% SDS–PAGE and
transferred to nitrocellulose membranes. The membranes were
blocked with 5% nonfat milk in PBST (1x PBS+0.1% Tween-20)
and probed with primary antibodies in 1% BSA. The signal was
detected by ECL (GE Healthcare) after incubation with the
appropriate HRP-conjugated secondary antibodies.
Measurement of PSA
PSA levels were measured in the culture supernatants using
ELISA (United Biotech Inc, Mountain View, CA) according to the
manufacturer’s instructions.
Real-Time Quantitative RT-PCR
LNCaP cells were transfected with the indicated plasmids or
oligonucleotides and total RNAs were extracted using Trizol
reagent (Invitrogen). cDNAs were prepared after digestion with
RNase-free RQ1 DNase (Promega). The cDNAs were subjected to
real-time reverse transcription-PCR (RT-PCR) using SYBR
Green iQ Supermix (Bio-Rad) according to the manufacturer’s
instructions and as described previously [26,27]. Reactions were
performed with 1 mL RT-PCR cDNA, 0.5 mL each of forward
and reverse primers (10 mmol/L), 10.5 mL double-distilled water,
and 12.5 mL iQ SYBR Green supermix. Each reaction was
normalized by coamplification of actin. Triplicates of samples
were run on default settings of Bio-Rad CFX-96 real-time cycler.
Primers used for quantification of Lin28 were: Forward 59-
GCCCCTTGGATATTCCAGTC-39 and Reverse 59-AATGT-
GAATTCCACTGGTTCTCCT-39. miRNA qPCR was per-
formed with the use of miRCURY LNA Universal RT microRNA
PCR kit and LNA-conjugated miRNA primers (Exiqon) according
to manufacturer’s instructions.
Northern Blotting
20 mg each of total RNAs from LNCaP, PC-3, DU145,
LNCaP-S17 and LNCaP-IL6+ cells were run on 15% Urea-
PAGE gels and transferred to nylon membranes. After UV cross
linking, membranes were hybridized to a probe recognizing the
mature sequence of let-7c. U6 snRNA was used as loading control.
miRNA in Situ Hybridization
In situ hybridization (ISH) was performed to determine the
patterns of expression of let-7c in human clinical PCa tissue
microarray containing 160 cores each from unmatched benign
and cancerous prostates. ISH was performed using the locked
nucleic acid (LNA)-conjugated let-7c-specific probe from Exiqon
according to manufacturer’s instructions.
Clonogenic Assays
Anchorage-dependent clonogenic ability assays were performed
as described previously [28]. Briefly, LNCaP cells transfected with
either empty vector or let-7c were seeded at low densities (400
cells/dish) in 10 cm culture plates. The plates were incubated at
37
oC in media containing either 10% FBS or 10% charcoal-
stripped FBS (CS-FBS) and were left undisturbed for 14 days. At
the end of the experiment, cells were fixed with methanol, stained
with crystal violet and the numbers of colonies were counted.
Soft-agar Colony Formation Assays
Anchorage-independent colony formation assays were per-
formed using C4-2B and LNCaP-S17 cells transfected with the
indicated plasmids. After transfection, cells were plated in 0.35%
agarose overlying a 1.2% agar layer. Cells were fed twice a week
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0C for
2 weeks. At the end of the experiment, colonies were stained with
0.005% Crystal Violet and counted.
Cell Growth Assays
LNCaP, C4-2B, DU145, LNCaP-S17 and LN-IL6+ cells were
transfected with plasmids expressing let-7c and viable cell numbers
were determined at 0, 24 and 48 h using a Coulter cell counter.
Apoptosis Assays using Cell Death Detection ELISA
DNA fragmentation in LNCaP, DU145, LNCaP-S17 and LN-
IL6+ cells transfected with plasmids as indicated in figures was
assessed by the Cell death detection ELISA kit (Roche,
Indianapolis, IN) according to the manufacturer’s instructions.
Generation of Stable Cell Lines
Stable cell lines of LNCaP and C4-2B expressing let-7c were
generated by transfection of plasmids containing the cDNAs and
selection of clones after application of selective pressure with
appropriate antibiotics.
Animals
6–8 week old male nude mice were maintained in the Animal
Facility at the UC Davis Medical Center. All experimental
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Figure 1. Let-7c is expressed in PCa cells. A) Total RNAs from LNCaP, PC-3, DU145, LNCaP-S17 and LN-IL6+ cells were analyzed by qRT-PCR.
Results are presented as relative fold change compared to expression levels in LNCaP. Data points represent mean 6 SD of triplicate samples from
two independent experiments. B)2 0mg each of the above RNAs were also analyzed by northern blotting. U6 snRNA was used as the loading control.
C) qRT-PCR showing the decrease in let-7c expression in LNCaP cells expressing Lin28 compared to LNCaP cells transfected with the empty vector
(Con). Inset Western blot shows expression of Lin28. D) qRT-PCR showing the increase in let-7c expression in C4-2B cells transfected with shRNA
against Lin28 compared to C4-2B cells transfected with control GFP shRNA. Inset Western blot shows downregulation of Lin28. Data points represent
mean 6 SD of triplicate samples from two independent experiments. Error bars denote 6 SD (*p , 0.05). E) Western blot showing the expression
levels of Lin28 in PCa cells. Actin is used as a loading control.
doi:10.1371/journal.pone.0032832.g001
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Figure 2. Let-7c expression is downregulated in human PCa. A) Relative expression levels of let-7c were measured by qRT-PCR in total RNAs
extracted from 10 paired benign and tumor human prostate samples. B) Let-7c levels were measured using in situ hybridization in TMAs containing
160 cores each from unmatched benign and cancerous prostate biopsies. Representative images are shown for benign and cancer cores. Expression
of let-7c was higher in benign prostates compared to cancerous prostates. C) Relative expression levels of Lin28 in the 10 paired benign and tumor
human prostate samples. Expression levels of Lin28 were correlated inversely with those of let-7c. Error bars denote 6 SD (*p , 0.05).
doi:10.1371/journal.pone.0032832.g002
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Animal Care and Use Committee of UC Davis. 1–2610
6 cells/
flank were injected s.c. into both flanks and tumors were allowed
to grow. Once the tumors reached 0.5 cm
3, 1x10
7 ifu (infectious
units) of lentiviruses containing either empty vector with GFP or
let-7c precursor were injected intratumorally. At the end of the
experiments, mice were sacrificed and tumors were excised. Sera
were collected for measurement of PSA.
Human PCa Specimens
Paired benign and tumor prostate tissues were prepared as
described previously [29]. Surgical specimens used in this study
were radical prostatectomy specimens (one from robotic surgery)
collected at the Johns Hopkins University from 2002 to 2007.
Specimens were selected from the frozen prostate tumor bank if
paired frozen blocks enriched for histologically normal and tumor
areas were available. Frozen blocks were manually trimmed to
further enrich the histology of interest. Cryosections (7 mm) were
prepared from each block before RNA extraction. The tumor
content in the tumor specimens was greater than 80%, whereas
normal samples had at least 60% epithelium content and no
evidence of tumor present. The first and last sections for each
block were H&E stained and used for % epithelium calculation.
The use of de-identified surgical specimens for molecular analysis
was approved by the IRB.
Statistical Analyses
Data are shown as means 6 SD. Multiple group comparison
was performed by one-way ANOVA followed by the Scheffe
procedure for comparison of means. P,0.05 was considered
significant.
Results
Let-7c is Expressed in PCa Cells
Our previous studies using miRNA microarrays showed that let-
7c was among the most commonly modulated miRNAs in PCa
cells (unpublished data). To determine the relative levels of
expression of let-7c in PCa cells, we isolated total RNAs from
LNCaP (androgen-dependent, AR-positive), PC-3, DU145 (cas-
tration-resistant, AR-negative) cells as well as LNCaP-S17 cells
expressing IL-6 [30] and LN-IL6+ cells chronically treated with
IL-6 [31]. cDNAs were analyzed by quantitative RT-PCR using
primers amplifying the mature form of let-7c (Exiqon) specifically.
Our results showed that let-7c is expressed at high levels in LNCaP
cells compared to the hormone-refractory PC-3 and DU145 cells
(Fig. 1A). Earlier reports showed that IL-6 and let-7 exhibit
reciprocal regulation of expression. LNCaP-IL6+ and LNCaP-S17
cells (autocrine IL-6 signaling) showed reduction in let-7c levels,
consistent with the report that IL-6 reduces let-7 expression in PCa
cells and that let-7 regulates IL-6 expression [18]. These results
were also confirmed by northern blotting using a probe against the
mature let-7c sequence (Fig. 1B), suggesting that let-7c levels are
reduced in more aggressive and castration-resistant PCa cells.
Recent reports showed that expression of let-7 family of
miRNAs is regulated by Lin28, a master regulator of miRNA
processing [18,20]. Consistent with the finding, we found that
overexpression of Lin28 led to a reduction in let-7c levels in
LNCaP cells (Fig. 1C), while downregulation of Lin28 using Lin28
shRNA led to an increase in let-7c levels (Fig. 1D) in C4-2B cells
which express endogenous Lin28 (Fig. 1E). Downregulation or
overexpression of Lin28 was confirmed by Western blotting (Inset
Fig. 1C&D). These results show that Lin28 plays a critical role in
regulation of let-7c expression in PCa cells.
Let-7c Expression is Downregulated in Human PCa
To determine whether the levels of let-7c expression are
downregulated in clinical PCa, we analyzed RNAs from 10 paired
benign and tumor human PCa specimens by quantitative RT-
PCR. RNAs were isolated from human tissues, reverse transcribed
and subjected to qRT-PCR using LNA-conjugated let-7c primers
(Exiqon). The levels of let-7c were significantly decreased in 8/10
tumors compared to their matched benign prostate tissues
(Fig. 2A). We also analyzed two tissue microarrays containing
benign and cancerous prostate biopsies respectively by in situ
hybridization using LNA-conjugated mature let-7c-specific probe
(Exiqon). The images were analyzed using an Olympus IX81
microscope and DP Controller Software. Our results showed that
let-7c was highly expressed in benign PCa, while its expression was
downregulated in the cancerous prostate (Fig. 2B). Collectively,
these results suggest that loss of let-7c expression may be associated
with prostate tumorigenesis.
Since Lin28 is a key regulator of let-7c expression, we examined
Lin28 expression in the 10 paired benign and tumor prostate
samples by qRT-PCR using primers which amplify Lin28 mRNA
specifically. Expression levels of Lin28 were found to be
significantly elevated in 9/10 pairs of matched benign and tumor
prostate specimens (Fig. 2C). Expression of Lin28 was correlated
inversely with expression of let-7c with a correlation coefficient of -
0.4, suggesting that let-7c expression is regulated primarily by
Lin28 in human PCa.
Let-7c Decreases the Growth of PCa Cells in Vitro
To determine whether let-7c affects the growth of PCa cells,
LNCaP, C4-2B, DU145, LNCaP-S17 and LN-IL6+ cells were
transfected with plasmids encoding let-7c or empty vector and
cell numbers were counted after 24 and 48 h. Cell numbers of all
PCa cell lines overexpressing let-7c were reduced by ,40% at
48 h (Fig. 3A-E). Insets show the levels of expression of let-7c
plasmid in these cells. To determine whether the observed
decrease in cell growth was due to apoptotic cell death, DNA
fragmentation was analyzed by Cell Death Detection ELISA. As
shown in Fig. 3F, apoptosis in cells overexpressing let-7c was
enhanced compared to the controls, suggesting that the inhibition
in cell growth induced by let-7c is partly due to increased
apoptotic cell death.
In addition, we tested whether downregulation of let-7c would
enhance the ability of androgen-sensitive PCa cells to grow in
androgen-deprived conditions. We transfected anti-sense oligos
Figure 3. Let-7c inhibits growth of human PCa cells in vitro. LNCaP (A), C4-2B (B), DU145 (C), LN-IL6+ (D) and LNCaP-S17 (E) cells were
transfected with let-7c or empty vector (Con) and cell numbers were determined after 24 and 48 h. Growth of PCa cells was suppressed by let-7c.
Insets show the levels of expression of let-7c plasmid. F) Cell death was analyzed in LNCaP, DU145, LNCaP-S17 and LN-IL6+ cells transfected with let-
7c or empty vector (Con). Let-7c induced apoptotic cell death of prostate cancer cells. G) LNCaP cells transfected with anti-sense oligos against let-7c
or scrambled oligos (Con) were grown in FBS and CS-FBS and cell numbers determined. Inset shows the downregulation of expression of let-7c by
anti-sense oligos. LNCaP cells with downregulated expression of let-7c exhibited faster growth in CS-FBS compared to controls. Data points represent
mean 6 SD of triplicate samples from two independent experiments. Error bars denote 6 SD (*p , 0.05).
doi:10.1371/journal.pone.0032832.g003
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supplemented with either FBS or charcoal-stripped FBS (CS-FBS)
and monitored cell growth. The results demonstrated that
downregulation of let-7c by anti-sense promoted androgen-
dependent LNCaP cell growth in conditions of androgen
deprivation (Fig. 3G). Downregulation of let-7c by the anti-sense
oligos was confirmed using qRT-PCR (Fig. 3G, inset). These
findings suggested that castration-resistant growth of PCa may be
characterized by downregulation of let-7c expression.
We also analyzed clonogenic ability of PCa cells expressing let-
7c in both anchorage-dependent and anchorage-independent
conditions. LNCaP-S17 and C4-2B cells were transfected with
let-7c or empty vector and colony formation assays were
performed. Both clonogenic (Fig. 4A) and soft agar colony
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Figure 4. Let-7c inhibits colony forming abilities of human PCa cells. Clonogenic (A) and soft agar colony forming (B) abilities of LNCaP-S17
and C4-2B cells transfected with let-7c or empty vector (Con) were assayed. Let-7c inhibited cell growth and survival in anchorage-dependent and –
independent conditions. C) Clonogenic assay-Upper and lower panels represent colony sizes of C4-2B and LNCaP-S17 cells expressing control (empty
vector) or let-7c respectively. D) Soft agar assay-Upper and lower panels represent colony sizes of C4-2B and LNCaP-S17 cells expressing control
(empty vector) or let-7c respectively. E) Number of colonies formed in clonogenic assay by C4-2B cells stably expressing let-7c. Let-7c decreased the
number of colonies formed by the PCa cells. Data points represent mean 6 SD of triplicate samples from two independent experiments. Error bars
denote 6 SD (*p , 0.05).
doi:10.1371/journal.pone.0032832.g004
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suppressed by overexpression of let-7c. The number of colonies
formed on substrata by LNCaP-S17 cells was reduced from
142615 to 46610 and the number of colonies formed by C4-2B
cells was reduced from 122610 to 3467 (Fig. 4A). Similarly, the
number of colonies formed in soft agar by LNCaP-S17 cells was
reduced from 8264t o1 5 62 and the number of colonies formed
by C4-2B cells was reduced from 6165t o2 1 65 (Fig. 4B) by
overexpression of let-7c. Furthermore, the size of colonies formed
by control-transfected cells was larger compared to the colonies
formed by let-7c-transfected cells (Fig. 4C&D). These results
suggest that let-7c may inhibit PCa cell growth in anchorage-
dependent as well as –independent conditions. These findings
were also confirmed with clonogenic assay in C4-2B cells stably
expressing let-7c (Fig. 4E).
Let-7c Inhibits Tumor Growth of Human PCa Cell
Xenografts
We generated lentiviruses encoding GFP-tagged let-7c precur-
sor using the Lentivector Expression System (System Biosciences).
To determine whether let-7c exhibits anti-proliferative effects on
PCa xenografts in vivo, we injected 2x10
6 C4-2B or PC346C (both
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Figure 5. Let-7c suppresses tumor growth of human PCa xenografts in vivo. C4-2B (A), PC346C (B) and DU145 (C) cells were injected into
both flanks of nude mice and the tumors received a single intratumoral injection of lentiviruses expressing either GFP (control) or let-7c. Tumor
growth was monitored twice weekly over 3 weeks. Data points represent mean 6 SD of tumor volume (mm
3) of all mice at the indicated time points.
D) Secretion of PSA by C4-2B and PC346C xenografts was measured in mouse sera by ELISA. Reconstitution of let-7c in the tumors reduced secretion
of PSA by the xenografts. At the end of the experiments, tumor tissues were excised, total RNAs prepared and subjected to qRT-PCR to assess mRNA
levels of let-7c (E) and Lin28 (F). Error bars denote 6 SD (*p , 0.05).
doi:10.1371/journal.pone.0032832.g005
Let-7c Inhibits Prostate Tumor Growth
PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e32832cell lines are AR-positive) cells s.c. into both flanks of male nude
mice and monitored tumor development. Once tumors reached
the size of 0.5 cm
3, mice were randomized into two groups. The
experimental mice received a single intratumoral injection of
lentivirally encoded let-7c, while control mice received lentiviruses
expressing GFP. Tumor growth was monitored over 3 weeks, with
tumor measurements twice weekly. At the end of 3 weeks, tumors
were excised, RNAs prepared and qRT-PCR performed to assess
levels of let-7c in the xenografts. The results showed that tumor
growth of C4-2B (Fig. 5A) and PC346C (Fig. 5B) xenografts was
inhibited significantly in mice injected with let-7c-containing
lentiviruses compared to mice injected with control lentiviruses. In
addition, we also tested whether let-7c can suppress tumor growth
of AR-negative xenografts. We injected 1x10
6 DU145 cells/flank
s.c. into male nude mice and performed similar experiments with
half the mice receiving a single intratumoral injection of
lentiviruses encoding let-7c and the other half receiving lentivi-
ruses encoding the empty vector. The results showed that let-7c
was successful in suppressing tumor growth of DU145 xenografts
similar to C4-2B or PC346C xenografts (Fig. 5C). Levels of PSA, a
classic target gene of AR, secreted by the AR-positive xenografts
were measured in the mouse sera using a human-specific PSA
ELISA kit and were normalized to tumor weights. Results showed
that injection of let-7c-expressing lentiviruses reduced the secretion
of PSA by the tumor xenografts of C4-2B and PC346C compared
to control lentiviruses (Fig. 5D). qRT-PCR showed that let-7c
levels were enhanced in the tumors injected with let-7c-encoding
lentiviruses, while levels of Lin28 were reduced (Fig. 5E&F). These
findings suggest that overexpression of let-7c suppresses prostate
tumor growth, and that reconstitution of let-7c levels may present
an attractive therapeutic strategy against human PCa.
Discussion
In this study, we found that let-7c expression is downregulated
in castration-resistant PCa cells and clinical specimens. Transfec-
tion of lentiviral-encoded let-7c inhibited the growth and
clonogenicity of PCa cells while enhancing apoptotic cell death.
Conversely, downregulation of let-7c by anti-sense oligonucleo-
tides conferred a survival advantage on PCa cells in androgen-
replete as well as androgen-depleted environments. Intratumoral
injection of lentivirally encoded let-7c inhibited PCa xenograft
tumor growth, demonstrating that let-7c functions as a tumor
suppressor that inhibits prostate tumor growth. These results
suggest that miRNA let-7c plays an important role in PCa cell
proliferation and may be exploited for therapeutic applications.
The mechanisms of suppression of prostate tumor growth by let-
7c may include direct or indirect regulation of expression levels of
oncogenes such as Myc and Lin28. In a recent report, we showed
that let-7c targets the expression of the AR via targeting the
expression of Myc [32]. The AR is a key survival factor for
prostate tumor cells and reduction of its expression has been
demonstrated to suppress prostate tumor growth [33]. In
confirmation of these findings, expression of PSA, one of the
classic target genes of the AR, was found to be suppressed by let-7c
in xenografts of C4-2B and PC346C cells in this study.
It is well documented that Lin28 plays a major role in regulation
of let-7c expression [18,21]. This is consistent with our studies
showing that Lin28 suppresses let-7c expression in PCa cells.
Overexpression of Lin28 inhibited let-7c expression in LNCaP
cells, while knockdown of Lin28 expression increased let-7c in C4-
2B cells. In addition, we demonstrated that overexpression of let-
7c reduced the levels of Lin28 expression in the tumors of PCa
xenograft models (Fig. 5F), indicating that a negative feedback
loop exists between Lin28 and let-7c.
Several reports have established the important role of let-7,
showing that members of the let-7 family are downregulated in
lung cancers and that this downregulation is correlated with poor
survival [8]. A tumor suppressor role has been attributed to the let-
7 family of miRNAs and appears to be undisputed except in rare
cases, such as let-7a, which has been reported to target caspase-3
in human cancers [34], thus suppressing susceptibility of cancer
cells to chemotherapeutic-induced cell death. In malignant
mesothelioma, let-7b* was found to be highly expressed [35]
and the upregulation of let-7b and let-7i was associated with high
grade transformation in lymphoma [36]. These conflicting data on
deregulation of let-7 in various human cancers show that
individual let-7 family members may have distinct and varying
activities in different cells and do not simply exhibit redundant
functions.
An earlier study by Dong et al. [37] reported that let-7a
suppresses prostate tumor growth by targeting E2F2 and CCND2.
Our studies suggest that let-7c suppresses prostate tumor growth
by several pathways including regulation of IL-6, Myc, Lin28 and
the AR [32]. In addition, direct reconstitution of let-7c by injection
of lentivirally encoded let-7c into established xenograft tumors
marks an important step in the direction of prospective therapeutic
strategies using let-7c. Even though members of the let-7 family
may exhibit some redundant functions, individual components
may be subject to differential and tissue-specific regulation in
different cell types. Our results with lentivirally encoded let-7c
show that, if feasible strategies to reconstitute let-7c in prostate
tumors can be developed, reconstitution of let-7c may represent a
potential therapeutic agent for PCa treatment.
In summary, our study demonstrates that the miRNA let-7c
plays an important role in inhibition of PCa cell proliferation and
castration-resistant progression. Downregulation of expression of
Let-7c and the let-7c/Lin28 feedback loop may facilitate prostate
tumor growth. Targeting this novel pathway may pave the way for
effective therapeutic strategies in PCa therapy.
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